Hunter Land is the associate director of cannabinoid research at Canopy Growth Corporation, the world’s largest cannabis producer. Previously, he was global project manager at GW Pharmaceuticals and established its US clinical team. There, Land authored Dravet syndrome, LGS, and multiple-sclerosis protocols and managed the clinical development of the FDA-approved CBD Epidiolex. He speaks at cannabinoid and scientific conferences and collaborates with cannabinoid, neurology, and epilepsy experts, focusing on applications of cannabinoid formulations and their application across a variety of conditions. Land is a co-founder of the Cannabinoid Education Working Group and a member of the International Cannabinoid Research Society, American Epilepsy Society, and the American Academy of Neurology.
Previously
Suddenly, CBD is everywhere – it’s being sold in major drugstore chains and showing up in skin lotion, smoothies, baked goods, lozenges, pet food, and Ben & Jerry’s ice cream....